Home › Researcher directory › Thomas D. Coates

Thomas D. Coates

Affiliation : University of Southern California · Children's Hospital Los Angeles

• 10Publications (affiliation in the United States)
• 447Total publications
• 14936Citations
• 63h-index

ORCIDOpenAlex

Research profile

Thomas D. Coates has 10 indexed publications (2018–2025). Their work appears mainly in “Blood”, “HemaSphere” and “The Lancet Haematology”. Their most cited article, “A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia” (2020), has been cited 332 times. 2 of these publications date from the last three years of activity. Their work is co-authored with at least 12 researchers, including institutions in Italy, France, Canada, Thailand.

Is this you? Get your research seen

Create your free DzCademia profile and add your articles: they will show up more easily on Google and in AI assistants like ChatGPT, so more people can read and cite your work.

Create my free profile Add my publications

Research areas

• Hemoglobinopathies and Related Disorders
• Iron Metabolism and Disorders
• Advanced MRI Techniques and Applications
• Blood transfusion and management
• Blood properties and coagulation

Publications (10)

• Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial
  2025 · The Lancet Haematology · cited 25 times
• Moderate–severe beta‐thalassemia intermedia phenotype caused by sextuplicated alpha‐globin gene allele in two beta‐thalassemia carriers
  2024 · American Journal of Hematology · cited 3 times
• S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY
  2022 · HemaSphere · cited 6 times
• P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA
  2022 · HemaSphere · cited 6 times
• A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
  2020 · New England Journal of Medicine · cited 332 times
• Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial
  2020 · Blood · cited 11 times
• Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial
  2020 · Blood · cited 8 times
• Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial
  2019 · Blood · cited 10 times
• Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions
  2019 · Blood · cited 3 times
• The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions
  2018 · Blood · cited 14 times

Publication venues

• Blood × 5
• HemaSphere × 2
• The Lancet Haematology × 1
• American Journal of Hematology × 1
• New England Journal of Medicine × 1

Publications per year

• 20251
• 20241
• 20222
• 20203
• 20192
• 20181

Collaborations

Partner institutions : University of Milan · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · University of Campania "Luigi Vanvitelli" · Ente Ospedaliero Ospedali Galliera · Azienda Ospedaliera G. Brotzu

Co-authors’ countries : Italy · France · Canada · Thailand

Co-authors

• Ashutosh Lal
• Peter G. Linde
• Abderrahmane Laadem
• Natalia Holot
• Ana Carolina Giuseppi
• Derek H. Tang
• Yu Tian
• George Zhang
• Matthew Leigh Sherman
• Olivier Hermine
• Jay T. Backstrom
• Daniel Sinsimer

Bibliographic data from OpenAlex (open database).